SIGHT SCIENCES, INC. (SGHT) Operating Margin
- Operating margin · 12 months: Value -33.43%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -33.43% | Operating income / revenue. Period ending 2026-06-30. $-27.87M ÷ $83.38M × 100 ≈ -33.43% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -27.87M USD | Operating Income (Loss) |
| Revenue | 83.38M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 10.04M USD | Cost of Goods and Services Sold |
| Research and development | 10.85M USD | Research and Development Expense |
| Selling, general and administration | 90.36M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-27.87M | $83.38M | $10.04M | $10.85M | $90.36M | -33.43% |
| 2026-03-31 | $-35.65M | $79.55M | $11.00M | $12.72M | $91.48M | -44.82% |
| 2025-12-31 | $-37.10M | $77.36M | $10.70M | $14.61M | $89.16M | -47.95% |
| 2025-09-30 | $-45.36M | $76.05M | $10.61M | $16.46M | $94.34M | -59.64% |
| 2025-06-30 | $-48.68M | $76.30M | $11.15M | $17.86M | $95.98M | -63.80% |
| 2025-03-31 | $-49.67M | $78.11M | $11.20M | $17.79M | $98.79M | -63.59% |
| 2024-12-31 | $-50.53M | $79.87M | $11.58M | $17.99M | $100.83M | -63.27% |
| 2024-09-30 | $-49.71M | $79.54M | $11.84M | $17.13M | $100.29M | -62.50% |
| 2024-06-30 | $-51.90M | $79.39M | $11.27M | $16.62M | $103.40M | -65.36% |
| 2024-03-31 | $-54.43M | $81.50M | $11.63M | $17.52M | $106.78M | -66.79% |
| 2023-12-31 | $-57.27M | $81.06M | $11.88M | $17.56M | $108.89M | -70.66% |
| 2023-09-30 | $-63.22M | $82.85M | $12.77M | $19.36M | $113.93M | -76.30% |
| 2023-06-30 | $-71.65M | $81.52M | $13.02M | $21.18M | $118.97M | -87.90% |
| 2023-03-31 | $-79.33M | $75.27M | $12.38M | $21.88M | $120.34M | -105.39% |
| 2022-12-31 | $-83.95M | $71.33M | $12.36M | $22.86M | $120.06M | -117.70% |
| 2022-09-30 | $-81.62M | $65.47M | $10.64M | $22.00M | $114.46M | -124.66% |
| 2022-06-30 | $-73.80M | $59.90M | $9.77M | $20.22M | $103.71M | -123.21% |
| 2022-03-31 | $-62.02M | $55.20M | $9.34M | $17.84M | $90.03M | -112.34% |
| 2021-12-31 | $-51.48M | $48.96M | $8.61M | $15.63M | $76.19M | -105.15% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-32.19M | $27.64M | $9.21M | $8.87M | $41.74M | -116.45% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NeuroPace Inc (NPCE) | United States | $0.480B | -28.52 |
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| SS Innovations International, Inc. (SSII) | $0.589B | -64.06 | |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |